BETA2,086.00

Beta Drugs Limited

· Unclassified
₹ CrorePeersTHEJOMACPOWERSAKARSERVOTECHMcap ₹2,115 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity16.9516.95
Return on Assets9.728.378.37
Return on Capital Employed18.6215.1015.10
Return on Invested Capital16.6723.10
Margins
EBITDA Margin20.5919.6720.19
Operating Margin17.1415.2115.21
Incremental Operating Margin-15.87
Pretax Margin15.7214.1314.98
Net Income Margin11.7110.7811.36
FCF Margin-1.45-4.21-4.21
Additional
Effective Tax Rate25.5423.7424.16
Sustainable Growth Rate16.9516.95
Incremental Operating Margin %-15.8718.34
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.